Dabrafenib

The addition of spartalizumab to dabrafenib and trametinib failed to prolong PFS among patients with BRAF-mutated advanced melanoma, according to results from the randomized phase 3 COMBI-i trial presented at ESMO Virtual Congress 2020.

A randomized phase 3 trial designed to evaluate the addition of spartalizumab to two targeted agents for the treatment of certain patients with advanced melanoma failed to meet its primary endpoint, according to the agent’s manufacturer.

The combination of dabrafenib and trametinib appeared active among patients with BRAF V600E-mutated biliary tract cancer, according to results of an ongoing phase 2 basket trial published in The Lancet Oncology.

Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.

Continuous dosing of dabrafenib and trametinib conferred superior PFS compared with intermittent dosing of the targeted agents among patients with BRAF V600E- and V600K-mutant melanoma, according to results of a randomized phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

CHICAGO — Bryan R. Haugen, MD, professor of medicine in the department of medicine-endocrinology, metabolism and diabetes at the University of Colorado School of Medicine received the 2019 Sydney H. Ingbar award during the Annual Meeting of the American Thyroid Association.